BRO — Brown & Brown, Inc.

Sentiment is subdued rather than panicked. The consensus rating is Hold (10 Buy / 20 Hold / 1 Sell) with a $72.50 average target and unusually wide dispersion ($55 low to $90 high; J.P. Morgan at $80, Morgan Stanley at $60). The early-September pullback of roughly 4-5% tracked broad risk-off in financials plus sector-wide insurance-broker consolidation headlines, and it reinforced a narrative shift: as of 2026-09-13 headline revenue is growing 34-37% YoY (Q1'26 +37.3%, Q2'26 +34.2%) but that is almost entirely Accession-driven, with core organic growth described as flat-to-slightly-negative against a softening P&C pricing cycle. The August 10, 2026 voluntary departure of EVP and former Retail President P. Barrett Brown added to the 'show me' mood, partly offset by the announced AI-first transformation with Anthropic, McKinsey and Accenture and the September 8-K reiterating full-year baselines.

Revenue roughly doubled from $972M in Q4'23 to $1.90B in Q1'26, but the shape is what matters. YoY growth ran a steady 8-12% through Q2'25, then stepped to +35.4% (Q3'25), +53.3% (Q4'25), +37.3% (Q1'26) and +34.2% (Q2'26) — an acquisition step-change (Accession), not an underlying-book acceleration, since the brief describes organic growth as flat-to-slightly-negative. Margins are noisy rather than cleanly expanding: Q2'26 operating margin of 33.8% looks strong against Q2'25's 27.0%, but Q2'25 was depressed by deal transaction costs, while Q1'26's 28.0% was 460bp BELOW Q1'25's 32.6%. TTM operating margin is 28.5%, which is a healthy broker-level number. The real crack is per-share: Q2'26 diluted EPS of $0.85 grew only ~9% YoY (+$0.07) on +34% revenue, because the Accession equity issuance took the share count from ~288M (Q1'25) to ~339M (Q2'26). Earnings quality is the bright spot — TTM free cash flow of ~$1.43B is up ~13% YoY, every quarter in the dataset is FCF-positive, capex runs only ~1.5% of revenue, and the accruals ratio of -0.19% at 2026-06-30 means cash generation is running ahead of reported net income. Net read: accelerating headline revenue, decelerating per-share growth, steady cash conversion. One flagged distortion: stockholders' equity jumped 70% between 2025-03-31 ($6.82B) and 2025-06-30 ($11.59B) on the Accession financing, so any growth comparison spanning that point is not organically meaningful.

As of 2026-09-13, BRO is cheap versus its own history and roughly fair-to-cheap versus broker peers. The stock trades at 18.3x trailing EPS against a 5-year average P/E of 26.7x, 3.23x sales against a 5-year average P/S of 5.17x, and ~14.7x the $4.49 consensus next-year EPS. EV/EBITDA of 12.2x is undemanding for a business with a 28.5% TTM operating margin and ~$1.43B of TTM free cash flow (a ~6.5% FCF yield at $66.19). The TTM PEG of 6.44 is mostly a data artifact — it divides post-deal, diluted trailing EPS by a trailing growth rate; on forward estimates the PEG is closer to 0.6-1.2. Dividend yield is modest at 0.93%. The honest caveat: the 32-38% discount to its own history is not pure mispricing — it reflects genuinely flat organic growth, a softening P&C rate cycle, and the leverage taken on for Accession (long-term debt $7.35B, D/E 0.64, net debt ~4.5x TTM FCF, up from $3.73B LT debt in Q1'25). This is a de-rated premium compounder, not a deep-value bargain.

At $66.19 the market is paying roughly 14.7x the $4.49 consensus next-year EPS — it has fully stopped paying the old ~26.7x premium multiple. The judgment call is whether that consensus number is real: it implies ~24% growth over the $3.619 TTM EPS, which requires Accession synergies, an end to dilution, and no further organic decay. If it lands, the stock is cheap and an 18-20x re-rating gets you to $81-90, consistent with the $90 high target. If organic stays flat and the share count keeps drifting up — as in Q2'26, when revenue rose 34% and EPS rose 9% — EPS growth settles into the high single digits and the current price is roughly fair. So this is a prove-it setup where the price already discounts disappointment. The stock will likely trade on two lines, not headline revenue: sequential organic growth and the expense ratio as evidence the AI program is more than a press release.

Weak, not yet washed out. As of 2026-09-13, RSI(14) stood at 35.4 — near but not at oversold — and the shares sat 6.65% below the 20-day (~$70.9), 5.69% below the 50-day (~$70.2) and 4.33% below the 200-day (~$69.2). The one-week return of -7.32% against a three-month return of +10.34% describes a failed rally and a fresh down-leg, not a basing pattern; the stock is in the lower third of its 52-week $53.81-$96.55 range. Entry-timing implication: there is no technical evidence of a bottom yet. RSI in the mid-30s frequently precedes a test of 30 before a turn. A close back above the 200-day (~$69) with RSI recovering through 45 is the first confirmation; failure at that level keeps the $53.81 52-week low in play. All levels are as of 2026-09-13 and will be stale when this is read.

• Softening P&C pricing cycle: commercial-line rate increases are moderating or flattening, which directly throttles organic commission growth for brokers regardless of premium volume.
• Interest rates and fiduciary income: elevated short rates boost investment income on held premiums (a tailwind), but high discount rates also compress the multiples investors pay for steady-growth financials — the single biggest driver of BRO's 31% drawdown from its 52-week high.
• Sector-wide insurance-broker de-rating: multiples across Aon, Marsh and Arthur J. Gallagher have compressed as organic growth slows, dragging BRO's relative valuation down with the group rather than on company-specific news.
• M&A financing costs and sector consolidation: BRO's roll-up model depends on debt markets for tuck-ins like MacKay; with $7.35B of long-term debt and 0.64x D/E, refinancing costs and deal capacity are rate-sensitive.
• AI/technology spending across brokerage: both an opportunity (margin expansion via the Anthropic/McKinsey/Accenture program) and a threat (disintermediation of traditional commission-based brokerage), which is why the market is scrutinizing the expense ratio.
• Benefits-market exposure: employment levels and medical cost trend drive the employee-benefits segment, adding a macro-linked revenue component alongside P&C.

• Q3'26 earnings (expected late October 2026): the first clean read on organic growth excluding Accession and on whether the AI program is moving the expense ratio.
• Quantitative evidence that the AI-first transformation is producing cost efficiencies rather than only consulting spend — a margin-driven re-rating trigger.
• Further tuck-in acquisitions (e.g., MacKay Corporate Insurance Brokers in Scotland) and successful cross-sell/retention of the Accession book.
• Share count stabilization or resumption of buybacks after the ~18% dilution from the Accession equity issuance (288M to ~339M shares).
• Analyst target and rating revisions after the September pullback (currently $55 low to $90 high, average $72.50), plus any change in the rate path affecting fiduciary income.

• Organic growth stays flat-to-negative: with the P&C pricing cycle softening, headline revenue growth would remain acquisition-dependent and the market would keep discounting the old premium multiple.
• Accession integration and dilution risk: share count up ~18% since Q1'25, long-term debt up from $3.73B to $7.35B, and net debt around 4.5x TTM free cash flow leaves less balance-sheet flexibility if integration slips.
• Persistent multiple compression: the stock was a 26.7x-average P/E name; there is no valuation floor that says it cannot settle into a mid-teens P/E if growth stays inorganic-only.
• Management turnover/execution risk: the August 10, 2026 voluntary departure of EVP Barrett Brown removes a senior retail operator precisely during the integration period.
• AI spend showing up in costs before it shows up in margins, temporarily compressing the 28.5% operating margin and undermining the efficiency narrative.
• Rate-driven valuation pressure: higher-for-longer discount rates would keep pressure on financial-sector multiples even if operating results hold up.

Brown & Brown is a genuinely high-quality, cash-generative broker wearing a 'show me' discount. The core economics are real: 28.5% TTM operating margin, ~$1.43B TTM free cash flow growing ~13% YoY, capex at ~1.5% of revenue, and a negative accruals ratio (-0.19%) meaning cash is running ahead of reported earnings. At $66.19 the stock is at 18.3x trailing and ~14.7x consensus next-year EPS versus a 5-year average of 26.7x. But the headline growth is bought, not earned — organic is flat-to-slightly-negative into a softening P&C rate cycle, and last quarter's +34% revenue translated to only +9% EPS once dilution is counted. That is why this is a Neutral, not a buy: the cheapness is real but it is compensating for a genuine slowdown and a de-rating that may not be finished, and the chart offers no confirmation of a bottom. The stock becomes interesting on either a push back toward the $53.81 low, or the first two quarters of positive sequential organic growth with a falling expense ratio. This is analysis, not personalized financial advice.

Three cross-checked methods, weighted evenly, as of 2026-09-13: (1) 16.5x the $4.49 consensus next-year EPS — a multiple ~38% below BRO's 5-year average P/E of 26.7x but in line with post-de-rating broker peers — gives ~$74; (2) a 5.75% required FCF yield on $1.43B of TTM free cash flow gives ~$24.9B of equity value, or ~$74/share on ~334.6M shares; (3) 13x EV/EBITDA on ~$2.35B of TTM EBITDA less ~$6.4B of net debt gives ~$72/share. The three average ~$73.5; I round to $73 to reflect flat organic growth and residual Accession integration risk.